Effect of montelukast in treatment of gastroenteritis
Phase 1
Recruiting
- Conditions
- Diarrhea.
- Registration Number
- IRCT20180624040213N3
- Lead Sponsor
- Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1. All patients with gastroenteritis, at any age 2 to 12 years and of both sexes, boys and girls are included in the study.
2. Patients with incurable disease or dangerous disease other than gastroenteritis.
3. Satisfaction of patients or their trustees (informed consent will be obtained from patients or patient trustees to participate in the study.)
Exclusion Criteria
Patients who develop a disease other than gastroenteritis during the study or find drug allergies
Refrain from collaborating with the research team during the study or refrain from taking medication and clinical examinations according to the study method.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measurement of serum interleukin level 13. Timepoint: Measurement of serum interleukin level 13 at the beginning of the study and 14 days after consumption of Montelukast. Method of measurement: Analysis of covariance (ANCOVA) will be used to evaluate the effect of montelukast on IL13 (before and after treatment) in both groups.
- Secondary Outcome Measures
Name Time Method Frequency of diarrhea and abdominal pain in the study of the effectiveness of Montelukast in the treatment of pediatric gastroenteritis. Timepoint: Evaluation of abdominal pain and frequency of diarrhea and measurement of serum level of interleukin 13 at the beginning of the study and 14 days after taking Montelukast. Method of measurement: How to measure the frequency of diarrhea excretion according to Bristol criteria, Evaluation of abdominal pain based on criteria Visual Analogue.